**APPENDIX A. Categorization of Infectious Problems**

|  |  |
| --- | --- |
| Group | Infectious Problems |
| Bacteremia | Bacteremia  Central-line associated blood stream infection |
| Bone and joint infection | Mastoiditis  Osteomyelitis  Septic arthritis |
| CNS infection | Encephalitis  Meningitis  Ventriculoperitoneal infection |
| Febrile neutropenia | Febrile neutropenia  Neutropenia (no fever) |
| Gastrointestinal/IAI | Appendicitis  Appendicitis with perforation  Intra-abdominal process  *C. difficile* infection  Necrotizing enterocolitis |
| Other | Atypical mycobacterium  Endocarditis  Lymphadenitis  Mediastinitis  Omphalitis  Orbital cellulitis  Skin and soft tissue infection  Retropharyngeal abscess  Surgical site infection |
| Prophylaxis | Postoperative prophylaxis  Preoperative prophylaxis  Prophylaxis |
| Respiratory infection | Acute chest syndrome  Aspiration pneumonia  Community acquired pneumonia, uncomplicated  Community acquired pneumonia, complicated  Cystic fibrosis exacerbation  Otitis media  Pneumonia  Presumed respiratory infection  Sinusitis  Tracheitis  Ventilator-associated pneumonia/hospital-associated pneumonia |
| Sepsis | Culture negative sepsis  Rule-out central-line associated blood stream infection  Rule-out sepsis  Sepsis with multiorgan decompensation  Sepsis/septic shock |
| Urinary tract infection | Urinary tract infection |

**APPENDIX B. Categorization of Antimicrobial Agents**

|  |  |  |  |
| --- | --- | --- | --- |
| Broad Spectrum Gram-Positive | Broad Spectrum Gram-Negative | Narrow Spectrum | Other |
| Daptomycin  Linezolid  Vancomycin | Amoxicillin-clavulanate  Ampicillin-sulbactam  Cefepime  Cefotaxime  Ceftazidime  Ceftriaxone  Cefuroxime  Ciprofloxacin  Imipenem  Levofloxacin  Meropenem  Moxifloxacin  Piperacillin-tazobactam  Tigecycline | Amikacin  Amoxicillin  Ampicillin  Azithromycin  Aztreonam  Cefazolin  Cefixime  Cefoxitin  Cephalexin  Clindamycin  Doxycycline  Erythromycin  Gentamicin  Metronidazole  Nafcillin  Penicillin  Rifampin  Sulfamethoxazole-trimethoprim  Tobramycin | Acyclovir  Amphotericin deoxycholate  Anidulafungin  Caspofungin  Cidofovir  Fluconazole  Foscarnet  Ganciclovir  Liposomal amphotericin  Micafungin  Oseltamivir  Posaconazole  Valganciclovir  Voriconazole |

**APPENDIX C. Categorization of Recommendation Type**

|  |  |
| --- | --- |
| Recommendation Type Group | Recommendation Type |
| Change agent | Broaden empirically  Change antibiotic (availability)  Change antibiotic based on culture/sensitivity  Narrow based on culture/sensitivity  Narrow empirically |
| Clarify | Clarify indication/plan |
| Duration modification | Duration suggestion  Lengthen duration  Shorten duration |
| IV to PO | IV to PO |
| No Change | No Change |
| Optimize dose or frequency | Decrease dose  Decrease frequency  Increase dose  Increase frequency |
| Other | ID Consult  Lab monitoring  Other |
| Stop | Stop (Consolidate to fewer agents)  Stop (No indication)  Stop (Redundant therapy) |

**APPENDIX D. Categorization of Provider Type Communicated Recommendation**

|  |  |  |
| --- | --- | --- |
| Infectious Diseases service | Pharmacist | Primary service |
| Infectious Diseases attending  Infectious Diseases fellow | Pharmacist  Pharmacy resident | Advanced practice provider  Medical fellow  Medical resident  Non-Infectious Diseases attending |